(OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 31 May 2026) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore” or the "Company”), a commercial-stage biotechnology company pioneering ...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...
NeuExcell Therapeutics today announced that Dr. Yulun Huang will present the first-in-human clinical study of NXL-004 for recurrent malignant glioma as Rapid Oral presentation at the 2026 Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results